Loading clinical trials...

TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer

Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer

NCT00052065•Telik

Summary

This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Histologically or cytologically confirmed diagnosis of epithelial cancer of the ovary, fallopian tube cancer or primary peritoneal cancer
•Recurrent epithelial ovarian cancer or persistent disease following primary treatment
•At least one, but no more than four, prior platinum-containing chemotherapy regimens
•At least one prior taxane-containing regimen

Exclusion Criteria

•A history of prior malignancy except for adequately treated carcinoma in situ of the uterine cervix, basal cell or squamous cell skin cancer, or other cancer for which the patient has been disease-free for 2 years
•Known leptomeningeal metastases or carcinomatous meningitis
•Have received prior Doxil or other liposomal doxorubicin
•Having received whole pelvis radiation therapy

Locations (1)

M.D. Anderson Cancer Center

Houston, Texas, United States

Key Dates

Start Date

February 1, 2003

Primary Completion Date

March 1, 2006

Completion Date

March 1, 2006

Last Updated

July 25, 2011

Enrollment

Estimated participants

Conditions

Ovarian Neoplasms

Interventions

TLK286

DRUG

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

NCT07213804

Ovarian NeoplasmsFallopian Tube Neoplasms+2 more

View study

RECRUITINGPHASE1/PHASE2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

NCT06051695

Solid Tumor, AdultColorectal Cancer+18 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 25, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer

Inclusion Criteria

Exclusion Criteria

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

Establishment of a Tumor Bank for Tissue Samples

Institut Paoli Calmettes Ovarian Cancer Database